{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:14:46Z","timestamp":1793060086778,"version":"4.5.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment of gram-negative bacterial infections exhibiting resistance to all traditional \u03b2-lactam and fluoroquinolone agents (ie, difficult-to-treat resistance [DTR]) poses challenges due to the limited number of active antibiotic agents. Managing DTR gram-negative infections becomes even more complex when present in the central nervous system due to concerns for insufficient concentrations of agents in the cerebrospinal fluid and brain parenchyma. Several newer \u03b2-lactam agents with activity against DTR gram-negatives are available, including cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, and sulbactam-durlobactam. This article examines host and drug factors that influence an antibiotic's effectiveness for the treatment of bacterial meningitis. The preclinical and clinical data in support of or against each of the aforementioned agents for the treatment of bacterial meningitis are also reviewed.<\/jats:p>","DOI":"10.1093\/cid\/ciaf071","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:11:11Z","timestamp":1740057071000},"page":"959-968","source":"Crossref","is-referenced-by-count":21,"title":["The Effectiveness of Newer Beta-Lactams for the Treatment of Antimicrobial-Resistant Gram-Negative Meningitis"],"prefix":"10.1093","volume":"80","author":[{"given":"Alice J","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Johns Hopkins Hospital , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0204-8708","authenticated-orcid":false,"given":"Kathleen","family":"Chiotos","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Critical Care, University of Pennsylvania, Perelman School of Medicine , Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-6684","authenticated-orcid":false,"given":"Emily L","family":"Heil","sequence":"additional","affiliation":[{"name":"Department of Practice, Sciences, and Health-Outcomes Research, University of Maryland School of Pharmacy , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-6324","authenticated-orcid":false,"given":"Pranita D","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Infectious Diseases, The Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"2025060412025566000_ciaf071-B1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2025060412025566000_ciaf071-B2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/myc.13157","article-title":"Antifungal drugs: an updated review of central nervous system pharmacokinetics","volume":"63","author":"Wirth","year":"2020","journal-title":"Mycoses"},{"key":"2025060412025566000_ciaf071-B3","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3390\/ijms23031898","article-title":"Blood-brain barrier transporters: opportunities for therapeutic development in ischemic stroke","volume":"23","author":"Nilles","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025060412025566000_ciaf071-B4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/dmd.112.049569","article-title":"Organic anion transporter 3 interacts selectively with lipophilic \u03b2-lactam antibiotics","volume":"41","author":"Wolman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"2025060412025566000_ciaf071-B5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QCO.0000000000000418","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections","volume":"31","author":"Nau","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"2025060412025566000_ciaf071-B6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med"},{"key":"2025060412025566000_ciaf071-B7","doi-asserted-by":"crossref","first-page":"e01698-20","DOI":"10.1128\/AAC.01698-20","article-title":"Cerebrospinal fluid penetration of ceftolozane-tazobactam in critically ill patients with an indwelling external ventricular drain","volume":"65","author":"Sime","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijantimicag.2019.06.021","article-title":"Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis","volume":"54","author":"Ohata","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025060412025566000_ciaf071-B9","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/jac\/dky128","article-title":"Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies","volume":"73","author":"Germovsek","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/AAC.39.1.232","article-title":"Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats","volume":"39","author":"De Sarro","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B11","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/archinte.1989.00390080131029","article-title":"Seizure propensity with imipenem","volume":"149","author":"Eng","year":"1989","journal-title":"Arch Intern Med"},{"key":"2025060412025566000_ciaf071-B12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0002-9343(88)90071-X","article-title":"Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem\/cilastatin","volume":"84","author":"Calandra","year":"1988","journal-title":"Am J Med"},{"key":"2025060412025566000_ciaf071-B13","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B14","author":"Shionogi & Co"},{"key":"2025060412025566000_ciaf071-B15","doi-asserted-by":"crossref","first-page":"S645","DOI":"10.1093\/ofid\/ofab466.1300","article-title":"1106. Evaluation of penetration of cefiderocol into cerebrospinal fluid using a rat meningitis model","volume":"8","author":"Takemura","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025060412025566000_ciaf071-B16","doi-asserted-by":"crossref","first-page":"ofac391","DOI":"10.1093\/ofid\/ofac391","article-title":"Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa ventriculitis using cefiderocol: a case report and literature review","volume":"9","author":"Marcelo","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025060412025566000_ciaf071-B17","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2025060412025566000_ciaf071-B18","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/jac\/dkac066","article-title":"Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis","volume":"77","author":"Luque-Paz","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B19","doi-asserted-by":"crossref","first-page":"dlac004.043","DOI":"10.1093\/jacamr\/dlac004.043","article-title":"P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol","volume":"4","author":"Stevenson","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025060412025566000_ciaf071-B20","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B21","first-page":"454","article-title":"Treatment with cefiderocol in K. pneumoniae KPC nosocomial external ventricular drainage meningitis: a brief report","volume":"30","author":"Colombo","year":"2022","journal-title":"Infez Med"},{"key":"2025060412025566000_ciaf071-B22","first-page":"A1617","article-title":"Ventriculostomy-related Acinetobacter meningitis","volume":"205","author":"Mak","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025060412025566000_ciaf071-B23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jgar.2022.11.019","article-title":"Intravenous cefiderocol for neurosurgical meningitis from an extensively drug-resistant New-Delhi metallo-beta-lactamase-producing Pseudomonas aeruginosa strain","volume":"32","author":"Stevenson","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2025060412025566000_ciaf071-B24","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/jac\/dkad277","article-title":"Plasmatic and CSF concentrations of cefiderocol in an infant with extensively drug-resistant Pseudomonas aeruginosa meningoencephalitis","volume":"78","author":"Funiciello","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/antibiotics13050453","article-title":"Role of cefiderocol in multidrug-resistant gram-negative central nervous system infections: real life experience and state-of-the-art","volume":"13","author":"Sollima","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025060412025566000_ciaf071-B26","first-page":"819","article-title":"Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis with sulbactam-durlobactam","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025060412025566000_ciaf071-B27","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B28","author":"GlaxoSmithKline Manufacturing SpA"},{"key":"2025060412025566000_ciaf071-B29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.26.1.115","article-title":"Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation","volume":"26","author":"Fong","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000457041","article-title":"Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis","volume":"8","author":"Blumer","year":"1985","journal-title":"Dev Pharmacol Ther"},{"key":"2025060412025566000_ciaf071-B31","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B32","author":"Cottagnoud"},{"key":"2025060412025566000_ciaf071-B33","author":"Pfizer Ireland Pharmaceuticals"},{"key":"2025060412025566000_ciaf071-B34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/microorganisms10010154","article-title":"Real-time optimization of pharmacodynamic target attainment at infection site during treatment of post-neurosurgical ventriculitis caused by carbapenem-resistant gram negatives with ceftazidime-avibactam-based regimens: a report of two cases","volume":"10","author":"Gatti","year":"2022","journal-title":"Microorganisms"},{"key":"2025060412025566000_ciaf071-B35","doi-asserted-by":"crossref","first-page":"ofaa349","DOI":"10.1093\/ofid\/ofaa349","article-title":"Using therapeutic drug monitoring to treat KPC-producing Klebsiella pneumoniae central nervous system infection with ceftazidime\/avibactam","volume":"7","author":"Yasmin","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025060412025566000_ciaf071-B36","doi-asserted-by":"crossref","first-page":"ofad507","DOI":"10.1093\/ofid\/ofad507","article-title":"Utilizing ceftazidime\/avibactam therapeutic drug monitoring (TDM) in the treatment of neurosurgical meningitis caused by difficult-to-treat resistant (DTR) Pseudomonas aeruginosa and KPC-producing Enterobacterales","volume":"10","author":"Yasmin","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025060412025566000_ciaf071-B37","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/00032719.2022.2105859","article-title":"Simultaneous determination of ceftazidime and avibactam in human plasma and cerebrospinal fluid by high-performance liquid chromatography\u2013tandem mass spectrometry (HPLC-MS\/MS)","volume":"56","author":"Wang","year":"2023","journal-title":"Anal Lett"},{"key":"2025060412025566000_ciaf071-B38","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2147\/IDR.S306222","article-title":"Successful treatment of ventriculitis caused by MDR\/XDR gram-negative bacillus using ceftazidime\/avibactam: case series and literature review","volume":"14","author":"Zhou","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2025060412025566000_ciaf071-B39","doi-asserted-by":"crossref","first-page":"ofac084","DOI":"10.1093\/ofid\/ofac084","article-title":"Intraventricular plus systemic antibiotic therapy for treating polymyxin-resistant Klebsiella pneumoniae ventriculitis: a case report","volume":"9","author":"Wang","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025060412025566000_ciaf071-B40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jac\/dkx358","article-title":"Ceftazidime\/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report","volume":"73","author":"Holyk","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2146\/ajhp170632","article-title":"Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin","volume":"75","author":"Gofman","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"2025060412025566000_ciaf071-B42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2016.11.005","article-title":"Clinical experience with ceftazidime\/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Xipell","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025060412025566000_ciaf071-B43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"2025060412025566000_ciaf071-B44","doi-asserted-by":"crossref","first-page":"e13082","DOI":"10.1111\/tid.13082","article-title":"Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis","volume":"21","author":"Dacc\u00f2","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2025060412025566000_ciaf071-B45","first-page":"572","article-title":"Nosocomial meningitis caused by ESBL- and OXA-48-producing Klebsiella pneumoniae and treated with ceftazidime-avibactam. Report of one case and review of the literature","volume":"35","author":"Valiente De Santis","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"2025060412025566000_ciaf071-B46","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/ofid\/ofw172.885","article-title":"Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae","volume":"3","author":"Samuel","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2025060412025566000_ciaf071-B47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jgar.2023.08.006","article-title":"Clinical and microbiological characteristics of carbapenem-resistant Enterobacteriaceae causing post-operative central nervous system infections in China","volume":"35","author":"Hu","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"2025060412025566000_ciaf071-B48","first-page":"23","article-title":"A fatal case of meningitis complicating chronic otitis media and base of skull osteomyelitis due to carbapenemase (OXA-48)-producing Klebsiella pneumoniae","volume":"5","author":"Baharoon","year":"2023","journal-title":"Dr Sulaiman Al Habib Med J"},{"key":"2025060412025566000_ciaf071-B49","doi-asserted-by":"crossref","first-page":"106777","DOI":"10.1016\/j.ijantimicag.2023.106777","article-title":"Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"61","author":"Zhao","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2025060412025566000_ciaf071-B50","doi-asserted-by":"crossref","first-page":"101832","DOI":"10.1016\/j.inat.2023.101832","article-title":"Case series: ceftazidime\/avibactam for treating post-neurosurgical ventriculitis and meningitis due to carbapenem-resistant Klebsiella pneumonia (CRKP)","volume":"34","author":"Pandey","year":"2023","journal-title":"Interdiscip Neurosurg"},{"key":"2025060412025566000_ciaf071-B51","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/INF.0000000000003439","article-title":"Ceftazidime-avibactam for the treatment of multidrug-resistant Pseudomonas aeruginosa central nervous system infection in pediatric patient: a case report","volume":"41","author":"Almangour","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"2025060412025566000_ciaf071-B52","first-page":"192","article-title":"Intravenous ceftazidime-avibactam in extremely premature neonates with carbapenem-resistant Enterobacteriaceae: two case reports","volume":"27","author":"Asfour","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2025060412025566000_ciaf071-B53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2147\/IDR.S403527","article-title":"Ceftazidime-avibactam treatment for severe post-neurosurgical meningitis and abscess caused by extended-spectrum \u03b2-lactamase Escherichia coli in a pediatric patient: a case report","volume":"16","author":"Ren","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025060412025566000_ciaf071-B54","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.eimc.2021.03.014","article-title":"Carbapenem-resistant Klebsiella pneumoniae meningitis and abscess treated with ceftazidime-avibactam","volume":"40","author":"Pektezel","year":"2022","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"2025060412025566000_ciaf071-B55","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/jac\/dkae035","article-title":"The pharmacokinetics\/pharmacodynamics of ceftazidime\/avibactam for central nervous system infections caused by carbapenem-resistant gram-negatives: a prospective study","volume":"79","author":"Xu","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B56","doi-asserted-by":"crossref","first-page":"e00963","DOI":"10.1016\/j.idcr.2020.e00963","article-title":"Carbapenemase producing Klebsiella pneumoniae (KPC) meningitis from chronic otitis media","volume":"22","author":"Anwar","year":"2020","journal-title":"IDCases"},{"key":"2025060412025566000_ciaf071-B57","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025060412025566000_ciaf071-B58","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025060412025566000_ciaf071-B59","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/antibiotics13010058","article-title":"New antibiotics for the treatment of nosocomial central nervous system infections","volume":"13","author":"Nau","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025060412025566000_ciaf071-B61","author":"Pfizer Europe MA EEIG"},{"key":"2025060412025566000_ciaf071-B62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/AAC.26.5.730","article-title":"Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges","volume":"26","author":"Duma","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B63","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijid.2021.09.064","article-title":"Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015\u20132018","volume":"112","author":"Pfaller","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2025060412025566000_ciaf071-B64","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B65","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1128\/AAC.41.5.987","article-title":"Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients","volume":"41","author":"Nau","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B66","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B67","author":"Merck & Co"},{"key":"2025060412025566000_ciaf071-B68","author":"European Medicines Agency"},{"key":"2025060412025566000_ciaf071-B69","doi-asserted-by":"crossref","first-page":"ofaa549","DOI":"10.1093\/ofid\/ofaa549","article-title":"Plasma and cerebrospinal fluid therapeutic drug monitoring of ceftolozane and tazobactam during treatment of multidrug-resistant Pseudomonas aeruginosa meningitis","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025060412025566000_ciaf071-B70","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s15010-020-01510-8","article-title":"Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis","volume":"49","author":"Winans","year":"2021","journal-title":"Infection"},{"key":"2025060412025566000_ciaf071-B71","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s15010-020-01539-9","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature","volume":"49","author":"Meschiari","year":"2021","journal-title":"Infection"},{"key":"2025060412025566000_ciaf071-B72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/reports5030033","article-title":"Off-label use of ceftolozane\/tazobactam for the successful treatment of healthcare-associated meningitis caused by extensively drug-resistant Pseudomonas aeruginosa in a polytraumatized patient\u2014a case report","volume":"5","author":"Dubler","year":"2022","journal-title":"Reports"},{"key":"2025060412025566000_ciaf071-B73","doi-asserted-by":"crossref","first-page":"e00451","DOI":"10.1016\/j.idcr.2018.e00451","article-title":"Ceftolozane-tazobactam and fosfomycin for rescue treatment of otogenous meningitis caused by XDR Pseudomonas aeruginosa: case report and review of the literature","volume":"14","author":"Frattari","year":"2018","journal-title":"IDCases"},{"key":"2025060412025566000_ciaf071-B74","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","article-title":"Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Dinh","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025060412025566000_ciaf071-B75","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B76","author":"Merck & Co"},{"key":"2025060412025566000_ciaf071-B77","first-page":"252","article-title":"Organic anion transporters also mediate the drug-drug interaction between imipenem and cilastatin","volume":"15","author":"Zhu","year":"2020","journal-title":"Asian J Pharm Sci"},{"key":"2025060412025566000_ciaf071-B78","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1128\/AAC.29.4.670","article-title":"Cerebrospinal fluid penetration of imipenem and cilastatin (Primaxin) in children with central nervous system infections","volume":"29","author":"Jacobs","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.seizure.2020.08.012","article-title":"Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations","volume":"81","author":"Wanleenuwat","year":"2020","journal-title":"Seizure"},{"key":"2025060412025566000_ciaf071-B80","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B81","author":"Merck & Co"},{"key":"2025060412025566000_ciaf071-B82","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/jac\/dkz101","article-title":"Role of transporters in the disposition of a novel \u03b2-lactamase inhibitor: relebactam (MK-7655)","volume":"74","author":"Chan","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B83","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B84","author":"The Medicines Company"},{"key":"2025060412025566000_ciaf071-B85","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1128\/AAC.42.8.2012","article-title":"Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy","volume":"42","author":"Nau","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B86","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/34.1.175","article-title":"Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges","volume":"34","author":"Dagan","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"2025060412025566000_ciaf071-B87","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B88","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijid.2022.07.073","article-title":"A post-neurosurgical infection due to KPC-producing Klebsiella pneumoniae treated with meropenem-vaborbactam: a case report","volume":"122","author":"Choi","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025060412025566000_ciaf071-B89","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/antibiotics13050432","article-title":"A difficult case of ventriculitis in a 40-year-old woman with acute myeloid leukemia","volume":"13","author":"Rubino","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025060412025566000_ciaf071-B90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/antibiotics13040331","article-title":"Meropenem-vaborbactam for the treatment of post-neurosurgical meningitis caused by KPC producer Klebsiella pneumoniae: a case report and review of the literature","volume":"13","author":"Rezzonico","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2025060412025566000_ciaf071-B91","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jgar.2024.03.003","article-title":"Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem\/vaborbactam and high dose of fosfomycin","volume":"37","author":"Volpicelli","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"2025060412025566000_ciaf071-B92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10096-024-04986-6","article-title":"Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports and review of the literature","volume":"44","author":"Giuliano","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025060412025566000_ciaf071-B93","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B94","author":"Entasis Therapeutics Ltd"},{"key":"2025060412025566000_ciaf071-B95","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1128\/AAC.31.11.1703","article-title":"Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis","volume":"31","author":"Foulds","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060412025566000_ciaf071-B96","author":"National Center for Biotechnology Information"},{"key":"2025060412025566000_ciaf071-B97","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"Int J Pharm"},{"key":"2025060412025566000_ciaf071-B98","doi-asserted-by":"crossref","first-page":"1381123","DOI":"10.3389\/fmed.2024.1381123","article-title":"Case report: successful treatment of OXA-23 Acinetobacter baumannii neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy","volume":"11","author":"Snowdin","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2025060412025566000_ciaf071-B99","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/clinids\/8.Supplement_5.S612","article-title":"Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy","volume":"8(Suppl 5)","author":"Stahl","year":"1986","journal-title":"Rev Infect Dis"},{"key":"2025060412025566000_ciaf071-B100","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1093\/clinids\/8.Supplement_5.S620","article-title":"Sulbactam\/ampicillin vs. chloramphenicol\/ampicillin for the treatment of meningitis in infants and children","volume":"8(Suppl 5)","author":"Rodr\u00edguez","year":"1986","journal-title":"Rev Infect Dis"},{"key":"2025060412025566000_ciaf071-B101","doi-asserted-by":"crossref","first-page":"S609","DOI":"10.1093\/clinids\/8.Supplement_5.S609","article-title":"Penetration of sulbactam into cerebrospinal fluid of patients with viral meningitis or without meningitis","volume":"8(Suppl 5)","author":"H\u00e4nninen","year":"1986","journal-title":"Rev Infect Dis"},{"key":"2025060412025566000_ciaf071-B102","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1093\/cid\/ciad095","article-title":"Durlobactam, a broad-spectrum serine \u03b2-lactamase inhibitor, restores sulbactam activity against Acinetobacter species","volume":"76","author":"Papp-Wallace","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025060412025566000_ciaf071-B103","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025060412025566000_ciaf071-B104","doi-asserted-by":"crossref","first-page":"e0031223","DOI":"10.1128\/aac.00312-23","article-title":"In vitro pharmacokinetics\/pharmacodynamics of the beta-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex","volume":"68","author":"O\u2019Donnell","year":"2024","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf071\/62010929\/ciaf071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/5\/959\/62010929\/ciaf071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/5\/959\/62010929\/ciaf071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:03:57Z","timestamp":1749053037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/5\/959\/8026377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":104,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,2,20]]},"published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf071","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,15]]},"published":{"date-parts":[[2025,2,20]]}}}